Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments.

R B Stoughton1

  • 1Division of Dermatology, University of California, School of Medicine, San Diego.

International Journal of Dermatology
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relation of application time to bioactivity of a potent topical glucocorticoid formulation.

Journal of the American Academy of Dermatology·1990
Same author

The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity?

Archives of dermatology·1989
Same author

In vitro and in vivo cutaneous penetration and antifungal activity of naftifine.

Cutis·1989
Same author

Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis.

Clinical therapeutics·1989
Same author

Percutaneous absorption of drugs.

Annual review of pharmacology and toxicology·1989
Same author

Adrenal suppression following low-dose topical clobetasol propionate.

Journal of the Royal Society of Medicine·1988
Same journal

Immune Checkpoint Inhibitors are Associated With Increased Risk of Lichen Planus in a TriNetX Analysis.

International journal of dermatology·2026
Same journal

Long Distance Non-Contact Dermoscopy: Technological Foundations, Clinical Applications, and Future Directions.

International journal of dermatology·2026
Same journal

Ulceronecrotic Plaques, Patchy Scalp Alopecia and Visual Disturbance in a 46-Year-Old Man.

International journal of dermatology·2026
Same journal

Beyond 1993: A Case Illustrating the 2021 Revised Criteria for Paraneoplastic Autoimmune Multiorgan Syndrome.

International journal of dermatology·2026
Same journal

Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study.

International journal of dermatology·2026
Same journal

Updated Vitiligo Trends in the Burden of Psychiatric and Autoimmune Diseases.

International journal of dermatology·2026
See all related articles

The vasoconstrictor assay reliably determines generic drug bioequivalence. Vehicle composition significantly impacts topical corticosteroid potency and efficacy, suggesting optimized application for reduced systemic absorption.

Area of Science:

  • Pharmacology
  • Dermatology
  • Drug Development

Background:

  • The vasoconstrictor assay is a key method for assessing bioequivalence of topical formulations.
  • Previous research has addressed practical application challenges of this assay.
  • Understanding formulation variables is crucial for accurate bioequivalence testing.

Purpose of the Study:

  • To evaluate the reliability of the vasoconstrictor assay for determining bioequivalence.
  • To investigate the impact of formulation vehicles on corticosteroid potency.
  • To analyze the relationship between corticosteroid potency and the time course of drug effects.

Main Methods:

  • Performing the vasoconstrictor assay on various topical corticosteroid formulations.
  • Analyzing differences in potency attributed to formulation vehicles.

Related Experiment Videos

  • Correlating corticosteroid potency with the onset and duration of vasoconstrictive effects.

    • Main Results:

    • The vasoconstrictor assay demonstrates high reliability for bioequivalence testing when performed correctly.
    • Significant vehicle-dependent variations in potency exist among supposedly equivalent generic formulations.
    • Higher potency corticosteroids generally exhibit earlier maximal effects compared to less potent ones.

    Conclusions:

    • The vasoconstrictor assay is a valuable tool for ensuring the bioequivalence of generic topical corticosteroids.
    • Formulation vehicle plays a critical role in the efficacy of topical corticosteroids.
    • Optimizing application duration for highly potent corticosteroids may reduce systemic absorption while maintaining therapeutic efficacy.